Advertisement

Banner Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Proteros Biostructures GmbH. (3/16/11). "Press Release: Proteros and CHDI Foundation, Inc. Establish Discovery Services Collaboration to Address Huntington’s Disease". Martinsried.

Organisation Organisation Proteros Biostructures GmbH
  Group Proteros (Group)
Products Product structure-based drug design
  Product 2 drug discovery services
Persons Person D’Cruz, Cony (Proteros 201008– CBO + President Proteros US Inc before Evotec SVP North America)
  Person 2 Herrenknecht, Kurt (SciArcum 201110– before Proteros + Zukunftsfonds Heilbronn + PerkinElmer + Evotec + Eisai)
     


Proteros Biostructures GmbH (Proteros) announced today that it has entered into a service agreement with CHDI Foundation, Inc. (CHDI), under which Proteros will provide structure-based drug discovery services to CHDI. Proteros will apply its integrated discovery platform including proprietary X-ray crystallography tools to help CHDI in its mission to develop therapeutics that slow the progression of Huntington.s disease (HD).

Cony D.Cruz Chief Business Officer and President Proteros US, Inc. stated, “CHDI has been at the forefront of using a best-in-class network to assist in developing therapies for HD. We welcome the opportunity for Proteros to contribute to this effort.”


About Proteros:

Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables .knowledge driven lead engineering. to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients. internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Japan. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America.


About CHDI Foundation:

CHDI Foundation, Inc. is a privately-funded, not-for-profit, scientific organization exclusively dedicated to rapidly discovering and developing therapies that slow the progression of Huntington.s disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. CHDI scientists work closely with a network of more than 600 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing project management to ensure that our common goals remain in focus. More information about CHDI can be found at www.chdifoundation.org.


Contact:

Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 0
E-Mail: herrenknecht@proteros.com
Internet: www.proteros.com

CHDI Foundation, Inc.
Simon Noble, Ph.D.
Director, Scientific Communications
CHDI Management/CHDI Foundation
Phone: +1 212 660 8112
E-Mail: Simon.noble@chdifoundation.org
Internet: www.chdifoundation.org

   
Record changed: 2014-04-23

Advertisement

Banner EBD Group BIO Europe 2014 BEU Frankfurt November 600x60px

More documents for Proteros (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Erfolgreicher Nischenanbieter im LC/MS-Markt sucht Junior-Partner 600x60px




» top

Advertisements

Banner EBD Group BIO Europe 2013 BEU Frankfurt November 120x120px Highl Successful LC/MS Niche Player Is Looking for a Junior Partner 120x240px The Events Group Pharm Connect Congress 2015 Budapest February 120x180px Banner C5 Communications Life Sciences IP Summit 2014 Amsterdam 120x180px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Banner [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px